This MedLibrary.org supplementary page on 4-androstene-3,6,17-trione is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
4-Androstene-3,6,17-trione
|
|
| Systematic (IUPAC) name | |
| (10R,13S)-10,13-dimethyl- 1,7,8,9,10,11,12,13,15,16- decahydro-2H-cyclopenta[alpha]phenanthrene- 3,6,17(14H)-trione |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C19H24O3 |
| Mol. mass | 300.39 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
unregulated, banned by World Anti-Doping Agency 1 |
| Routes | oral |
 |
This article uses citations that link to broken or outdated sources. Please improve the article or discuss this issue on the talk page. Help on using footnotes is available. May 2008 |
4-Androstene-3,6,17-trione (also marketed as "6-OXO" or 4-etioallocholen-3,6,17-trione) is a drug or nutritional supplement that may increase the testosterone-estrogen ratio. Its use can be detected in urine.2 3
4-Androstene-3,6,17-trione (4-AT) is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. 456 Aromatase is responsible for the conversion of testosterone to estradiol. Blocking aromatase causes the body to decrease in levels of estradiol, which then results in increase of LH and consequently, testosterone. Since testosterone has myotropic activity and estradiol does not, elevated testosterone levels increase muscle mass. However, there appear to be no human or animal studies testing the hypothesis that 4-AT will produce an anabolic effect.
4-AT is also used by steroid or prohormone users to counteract estrogen level increases caused by aromatization during their steroid cycle. This helps minimize side effects such as gynecomastia but can lead to acne. Also, after a steroid cycle, the compound may be used to shorten the recovery from the testicular suppression that can be the result of the use of steroids.
A recent United States patent application claims an 88% increase in plasma testosterone levels in men, while decreasing estrogen levels by 11%.7 The subjects took 300mg orally twice a day for four weeks without taking any other drugs or supplements.
Baylor University conducted an eight-week study to determine the effects of 300 mg or 600 mg of 6-OXO in resistance-trained males. Compared to baseline, free testosterone increased by 90% for 300 mg group and 84% for 600 mg group, respectively. Also dihydrotestosterone and the ratio of free testosterone to estradiol increased significantly. This study did not utilize a control group and was funded in part by two producers of commercial 4-AT.89
In a warning letter dated July 7, 2006, the FDA argues that marketing of 4-AT (aka, 6-OXO) violates the Federal Food, Drug, and Cosmetic Act and as such products containing it are adulterated by legal definition.
On June 18, 2008, Health Canada issued a warning that 4-AT and 6-OXO had a health risk related to blood clotting and recommended all users immediately cease use.
Usage
A typical dosage regimen is 200-600mg orally once a day in the evening, for a 4-6 week cycle.
References
- ^ The World
- ^ J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 15;828(1-2):21-6 -Regarding detection of 6-OXO in urine
- ^ Van Thuyne W, Van Eenoo P, Mikulcíková P, Deventer K, Delbeke FT. (2005). "Detection of androst-4-ene-3,6,17-trione (6-OXO) and its metabolites in urine by gas chromatography-mass spectrometry in relation to doping analysis.". Biomed Chromatogr. 19: 689. doi:. PMID 15828056.
- ^ Numazawa M, Tsuji M, Mutsumi A (1987). "Studies on aromatase inhibition with 4-androstene-3,6,17-trione: its 3 beta-reduction and time-dependent irreversible binding to aromatase with human placental microsomes". J Steroid Biochem. 28(3) (Sep): 337–44. doi:. PMID 3657156.
- ^ Covey DF, Hood WF. (1981). "Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity". Endocrinology 108 (4): 1597–9. PMID 7472286.
- ^ Hsueh AJ, Erickson GF. (1978). "Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells". Steroids 32 (5): 639–48. doi:. PMID 734698.
- ^ Patent application:"Use of 4-androstene-3,6,17-trione to elevate testosterone levels and the testosterone/estrogen ratio in males"
- ^ Rohle D, Wilborn C, Taylor L, Mulligan C, Kreider R, Willoughby D. (2007). "Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males.". J Int Soc Sports Nutr. 4: 13. doi:. PMID 17949492.
- ^ Muscle & Fitness: The science of 6-OXO
Wikipedia content modification information:
- This page was last modified on 7 January 2009, at 15:29.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "4-androstene-3,6,17-trione".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.